导师代码：12194
导师姓名：蔡璐璐
性　　别：女
出生年月：1984年07月
特　　称：四川省人社厅学术和技术带头人后备人
职　　称：副研究员
学　　位：博士
属　　性：专职
电子邮件：cailulu@med.uestc.edu.cn



导师代码 12194 性别 女
出生年月 1984年07月 职称 副研究员
属性 专职 电子邮件 cailulu@med.uestc.edu.cn
特称 四川省人社厅学术和技术带头人后备人 学位 博士
2018/9-至今，美国加州大学洛杉矶分校（UCLA）, 生物工程系, 访问助理项目科学家，合作导师， 顾臻 教授；2017/5-2018/8，美国北卡罗来纳大学教堂山分校/北卡罗来纳州立大学, 生物医学工程系, 博士后助理，合作导师， 顾臻 教授；2016/5-2017/5，电子科技大学医学院(四川省人民医院), 药学部, 副研究员；2014/6-2017/5，四川大学, 生物治疗国家重点实验室，在职博士后，导师：魏于全 院士；2014/5-2015/5，日本京都药科大学, 药剂学分野，中国卫生部-日本医学协会第34期“笹川医学奖学金”进修生，导师：山本 昌 教授2012/7-2016/4，四川省人民医院，药学部，助理研究员；2007.09-2012.07 四川大学生物治疗国家重点实验室 硕博连读 药学博士
学术经历：
蔡璐璐，副研究员，博士，硕士研究生导师，四川省人社厅学术和技术带头人后备人, 主持国家自然科学青年基金及四川省****科学基金。中国医药生物技术协会纳米生物技术分会委员，四川省药学会药物流行病学专委会委员，中国抗癌协会纳米肿瘤学专业委员会专业会员，中国抗癌协会肿瘤药物临床研究专业委员会专业会员，中国抗癌协会肿瘤精准治疗专业委员会专业会员，中国抗癌协会肿瘤分子医学专业委员会专业会员，免疫学会肿瘤免疫学分会会员, 成都药学学会会员。 近十年来致力于肿瘤治疗领域新药新制剂的研究与开发。先后承担了国家自然科学青年基金，国家博士后基金面上项目，四川省****科学基金，四川省科技厅科技支撑项目，四川省卫生计生委应用基础项目，四川省中医药管理局青年项目等各级科研项目，曾参与863国家级科研项目、科技部“十一五”药物重大专项资助和四川省科技厅科技攻关重点项目等各级项目。主要研究成果发表在 Nano Research (IF=7.994), Nanoscale (IF=7.233)，Drug Discovery Today (IF=6.369)，J Biomed Nanotechnol (IF=5.068), J Mater Chem B (IF=4.776)，Int J Nanomed (IF=4.370)及Int J Pharm (IF=3.862) 等SCI杂志上30余篇。论文被Nat Rev Microbiol, Pharmacol Rev， Nanotoxicology，J Control Release，Biomaterials，Cancer Treat Rev等国际期刊引用600余次，H因子13 (Google Scholar数据)。同时受邀担任Nano Research, Nanoscale, Biomaterials, Int J Pharm, Int J Nanomed等国际杂志的审稿人。已申请纳米药物方向中国发明专利7项。
个人简介：
主要涉及肿瘤治疗领域新药新制剂的研究与开发。主持国家自然基金青年基金1项；中国博士后面上基金1项；四川省****科技基金1项；四川省科技厅科技支撑计划项目1项; 四川省卫生计生委应用基础项目1项；四川省中医药管理局青年项目一项；四川省人社厅留学择优资助项目1项；与企业合作横向项目1项。
科研项目：
近年来主要代表作：1.Advances in glycosylation-mediated cancer-targeted drug delivery. Drug Discovery Today, 2018, 23(5), 1126-1138.2.Tumor microenvironment-responsive hyaluronate-calcium carbonate hybrid nanoparticle enables effective chemotherapy for primary and advanced osteosarcomas. Nano Research, 2018, 11(9): 4806–4822.3.Synthesis, mechanical investigation, and application of nitrogen and phosphorus co-doped carbon dots with a highly photoluminescent quantum yield. Nano Research, 2018, 11(7): 3691–3701.4.Multidimensional theranostics for tumor fluorescence imaging, photoacoustic imaging and photothermal treatment based on manganese doped carbon dots. J Biomedical Nanotechnology, 2018, 14 (9), 1590-1600.5.Gambogic acid-loaded polymeric micelles for improved therapeutic effect in breast cancer. J Biomedical Nanotechnology, 2018,14 (10), 1695-1704.6.Synthesis of highly fluorescent yellow‐green N‐doped carbon nanorings for pH variation detection and bioimaging. Particle & Particle Systems Characterization, 2018:**.7.The application of natural products in cancer therapy by targeting apoptosis pathways. Current drug metabolism, 2018,19 (9), 739-749.8.Efficient cocktail chemotherapy by co-delivery of hydrogen sul?de-releasing aspirin prodrug and paclitaxel via single nanoparticles. RSC Advances, 2017, 7, 13458–13466.9.Highly fluorescent Zn-doped carbon dots as Fenton reaction-based bio-sensors: an integrative experimental–theoretical consideration. Nanoscale, 2016, 8(41): 17919-17927.10.Heteroatom-doped carbon dots: synthesis, characterization, properties, photoluminescence mechanism and biological applications. Journal of Materials Chemistry B, 2016, 4(45): 7204-7219.11.Comparative study of (Asp) 7-CHOL modified liposome prepared using pre-insertion and post-insertion methods for bone targeting in vivo. Journal of Drug Targeting, 2016, 25:149–155. 12.An integrated in silico method to discover novel rock1 inhibitors: multi-complex-based pharmacophore, molecular dynamics simulation and hybrid protocol virtual screening. Combinatorial chemistry & high throughput screening, 2016, 19: 36-50.13. Computational analysis of spiro-oxindole inhibitors of the MDM2-p53 interaction: insights and selection of novel inhibitors. Journal of Biomolecular Structure and Dynamics, 2016: 34(2), 341-351.14.Novel naproxen-peptide-conjugated amphiphilic dendrimer self-assembly micelles for targeting drug delivery to osteosarcoma cells. RSC Advances. 2016, 6: 60327-60335.15.Barbigerone-in-hydroxypropyl-β-cyclodextrin-liposomal nanoparticle: preparation, characterization and anti-cancer activities. Journal of Inclusion Phenomena and Macrocyclic Chemistry, 2015, 82(3-4): 505-514.16.Synthesis and in vitro evaluation of 4-substituted furano [3, 2-c] tetrahydroquinolines as potential anti-cancer agents. Journal of enzyme inhibition and medicinal chemistry, 2015: 1-6.17.Improving aqueous solubility and antitumor effects by nano-sized gambogic acid-mPEG2000 micelles. Int J Nanomedicine. 2014, 9: 1-13.18.Peptide ligand and PEG-mediated long-circulating liposome targeted to FGFR over-expressing tumor in vivo. Int J Nanomedicine. 2012, 7: 4499-510. 19.Preparation of the thienopyridine derivatives loaded liposomes and study on the effect of compound-lipid interaction on release behavior. Drug Deliv. 2012, 19(5): 247–254. 20. A systemic administration of liposomal curcumin inhibits radiation pneumonitis and sensitizes lung carcinoma to radiation. Int J Nanomedicine. 2012:7 2601–2611. 21.Liposomal curcumin inhibits Lewis lung cancer growth primarily through inhibition of angiogenesis. Oncology Letters. 2012, 4: 107-112.22.A novel truncated basic fibroblast growth factor fragment-conjugated poly (ethylene glycol)-cholesterol amphiphilic polymeric drug delivery system for targeting to the FGFR-overexpressing tumor cells. Int J Pharmaceut. 2011, 408: 173–182.23.Improved solubility and pharmacokinetics of PEGylated liposomal honokiol and human plasma protein binding ability of honokiol. Int J Pharmaceut. 2011, 410: 169–174. 24. Truncated bFGF-mediated cationic liposomal paclitaxel for tumor-targeted drug delivery: Improved pharmacokinetics and biodistribution in tumor-bearing mice. J Pharm Sci. 2011, 100: 1196–1205.25.Preparation, Characterization, Pharmacokinetics and Bioactivity of Honokiol-in-Hydroxypropyl-β-Cyc-lodextrin-in-Liposome. J Pharm Sci. 2011, 100: 3357–3364. 26.Synthesis, structural and in vitro studies of well-dispersed monomethoxypoly (ethylene glycol)–honokiol conjugate micelles. Biomed mater. 2010, 5: 065006.27.Improved tumor-targeting drug delivery and therapeutic efficacy by cationic liposome modified with truncated bFGF peptide. Journal of Controlled Release, 2010, 145(1): 17-25.28. Schistosoma japonicum: efficient and rapid purification of the tetraspanin extracellular loop 2, a potential protective antigen against schistosomiasis in mammalian. Exp Parasitol. 2010, 126: 456-461.
发表文章：
硕士招生专业105500 药物研究与转化
02方向： 药物研究与转化
博士招生专业